Clinuvel Pharmaceuticals Limited
CUVLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Clinuvel Pharmaceuticals Limited focuses on Biotechnology services and products. Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland,. At a $303.1M market cap, Clinuvel Pharmaceuticals Limited ranks as a small-cap company within healthcare. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Market Cap
$303.1M
Beta
0.56
P/E (TTM)
12.52
P/E (Fwd)
—
EPS (TTM)
$0.48
EPS (Fwd)
—
ROE
13.2%
ROA
8.9%
Cash
$252.1M
Total Debt
$1.9M
Free CF
$25.4M
52W Change
-9.7%
Annual Financials
Cash vs Debt
Where CUVL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CUVL finished 11.36% below its 150-day moving average ($7.04) and 14.29% below its 200-day moving average ($7.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CUVL overbought or oversold?
At the September 2, 2026 close, CUVL's RSI(14) was 44.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Clinuvel Pharmaceuticals Limited holds $252.1M in cash against $1.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $25.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 13.2% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $78.3M (2023) to $94.0M (2026), reflecting a 20% increase over the period.
With a beta below 0.7, Clinuvel Pharmaceuticals Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CUVL.